- Country profiles
- Data dashboard
- Satellite Pages
- About us
- WHAT'S NEW
This paper provides an overview of the challenges of financing health care in the region, where many countries are striving to achieve universal health coverage. It examines the contributions of the public and private sectors, and considers the future of external development aid. The paper concludes with reflections on the implications for development partners, discussing how policy issues can be tackled, how aid modalities should develop and where donor assistance should be focused to maximise impact.
The HIV Investment Framework (IF) is a model for HIV and AIDS investment and prioritisation for maximum impact. The IF advocates for a short-term increase in HIV funding in order to reduce funding requirements over the long term. IF is aligned to the investment thinking approach to resourcing of the HIV response. This means treating resources for the HIV response as investments that will deliver returns, rather than as expenses that will always have gaps demanding to be filled.
To provide some perspective on the geographic presence of global health donors and to help stakeholders begin to answer some of the above questions, the Kaiser Family Foundation is undertaking a series of analyses to describe the global health “donor landscape.” Using three years of data from the Organisation for Economic Co-operation and Development (OECD), we map the geographic landscape of global health donor assistance, looking both at donor presence and magnitude of donor assistance by issue area, region, and country. The effort is intended to shed new light on donor presence within and across recipient countries, and to produce a set of figures and tools that stakeholders can use in both donor and recipient countries.
HIV investment cases provide an important vehicle for countries to deliver strategic, rights-based, sustainable responses to HIV. The process of developing investment cases provides countries with new opportunities to explore options for innovative funding and service delivery, to identify specific steps to enhance equity and inclusiveness for key populations, to use available evidence to understand better the health and economic benefits of timely, rights-based, smart HIV investments and to eliminate inefficiency in HIV programmes.
HIV and AIDS are among health issues prioritized in the Millenium Development Goals (MDGs) and require considerable attention from various stakeholders. The Government of Indonesia, along with international partners has been working hard in suppressing the spread of AIDS in the country through various programs. However, more challenges remain, and despite considerable amount of money spent in resources to combat HIV and AIDS in Indonesia, the rate of new cases of HIV continue to persist.
Keywords: NASA, expenditures, spending, prevention, treatment, vulnerable
This summary report is intended to provide the pricing data of key ARVs to governments, nongovernmental organizations, donors, international organizations, academia and individuals or institutions directly involved or interested in the procurement of ARVs in resource-poor settings.
This report provides the findings of a comprehensive evaluation on the implementation, management, estimated population impacts, and cost-effectiveness of the DFID and the World Bank funded harm reduction programmes in Vietnam. It mainly included three major components: (1) an extensive literature review of legal and policy documents to understand key changes in the legal and policy environment in Vietnam; (2) a qualitative study utilising focus groups with key stakeholders and programme participants to provide background and context for understanding the implementation, management and effectiveness of the DFID/WB programmes; (3) a quantitative assessment of population impacts and cost-effectiveness of DFID/WB programmes based on a mathematical model.
This project aimed to assess whether the harm reduction programme in Malaysia, which consists of NSP and MMT programmes amongst PWID, have been cost-effective from the perspective of the government by estimating savings in direct health care cost to the government resulting from infections that were averted as a result of the NSP and MMT programmes. The following estimates were included in the estimate of savings in direct health care costs; estimate the cost-effectiveness of the NSP and MMT programmes in terms of costs for the provision of programmes net of health care cost savings for each quality-adjusted-life years (QALYs) gained; estimate the return on investment (ROI) from NSP and MMT programmes where ROI refers to total health care costs saved from averted infections in comparison to total programme costs.
The Global Fund Results Report 2012 presents the latest data from recipients of Global Fund grants in 151 countries – as well as the latest evidence of impact on the HIV, tuberculosis (TB) and malaria pandemics, and the most up-to-date information on Global Fund financing. It highlights the continued progress and the scale-up achieved by low- and middle-income countries around the world, made possible by the collaboration and efforts of hundreds of governments, donors, recipients, technical agencies, private companies and civil society organizations.
The Fiji Government, via the National HIV Board, is pursuing a robust initiative to capture strategic information regarding the national response to HIV & AIDS vis-à-vis the tracking of financial information from financing sources to actual expenditures.
Keywords: HIV response, NASA, financing, prevention, care, treatment, PLHIV, most at risk populations